In a pivotal trial including 18 patients, the pharmacokinetics of Myozyme were evaluated in 15 patients with infantile-onset Pompe disease (all aged less than 6 months at treatment-onset) who received doses of 20 mg/ kg or 40 mg/ kg alglucosidase alfa as an approximate 4 to 6.5-hour infusion, respectively.